With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.
News|Articles|October 24, 2007
NextWave, Kerr Drug team up to offer MyKidz Iron
NextWave Pharmaceuticals and Kerr Drug to provide MyKidz Iron
Advertisement
NextWave Pharmaceuticals and Kerr Drug are teaming up to offer MyKidzIron, a nonprescription liquid iron supplement that uses new suspension technology to deliver elemental iron, which is said to offer a great taste without staining clothes or teeth. According to CDC, iron deficiency is a major cause of anemia in the U.S. MyKidz Iron is available in berry/banana flavor. For more information, visit
To see more Hot off the Press news articles,
To go to the Drug Topics homepage,
Advertisement
Related to this article
Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.
The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.
Teva Pharmaceuticals’ new olanzapine option is the first once-monthly subcutaneous injectable on the market for schizophrenia.
Investigators link oversight with eroding trust in health authorities and call on future pandemic inquiries to weigh trade-offs.
Lara Zakaria, PharmD, MS, CNS, FMCP, illustrates the breadth of health technology going in and out of community pharmacy practice.
Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Network Terminations Bring Risks Beyond Lost Contracts | NCPA 2026
2
Harms of Public Health Measures Overlooked in COVID-19 Policy Reviews
3
FDA Approves First Generic for Climara Pro Hormone Therapy Patch
4
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
5